At the upcoming annual meeting of the American Society of Gene and Cell Therapy, scientists from Huidagene Therapeutics will share an update on the development of their ...

Using CRISPR co-culture screens, researchers found that deleting CHD1 and MAP3K7 makes tumor cells more vulnerable to immune ...

Picture CRISPR-Cas9, a gene editing technology, as a GPS-guided scalpel: gRNA directs the Cas9 enzyme, a protein that cuts ...

Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins are core components of fast-evolving therapeutic gene editing tools. Scientists have used CRISPR ...

CRISPR has the power to correct genetic mutations, but current delivery methods are either unsafe or inefficient, keeping the technology from reaching its full medical potential. With the power to ...

If the first CRISPR decade was marked by a mad dash to evolve, engineer, and mine the bacterial universe for more and better genome-editing enzymes, so far the second seems to be all about three words ...

(RTTNews) - Vertex Pharmaceuticals (VRTX), Thursday reported compelling long-term data for its CRISPR/Cas9 gene-edited therapy, PrCASGEVY, at the EHA Congress. In sickle cell disease trials, 95.6 ...

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and anticipated ...

Crispr Therapeutics, in collaboration with Vertex, pioneered the first CRISPR-based gene therapy, Casgevy, with regulatory approval in multiple countries, poised for strong revenue growth from Q4 2024 ...